Category: C.R. Bard
Executives at C.R. Bard say the company is on track for an early 2015 approval for its Lutonix drug-eluting balloon for treating peripheral artery disease.
C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.
Covidien says its exposure to a raft of product liability lawsuits filed over pelvic mesh products increased by some $131 million during its fiscal 3rd quarter.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA wants another panel hearing on Boston Scientific's Watchman anti-stroke device; FDA talks Twitter and other online etiquette for medtech makers; Malaysian medical device market regulators clarify, expand policies; FDA issues draft guidances for industry on social media and internet communications about medical products: Designed with patients in mind; Scotland curbs use of transvaginal mesh amid global outcry.
Scotland's regional health boards agree to suspend use of transvaginal mesh implants pending an investigation into complaints that the devices scar women for life.
Scottish health regulators are looking to curb use of transvaginal mesh products while independent investigators look into claims that the medical implants hurt women.
Here's a look at some of the top regulatory stories for medical device companies this week: Digital health: Inside Apple's meeting with the FDA; FDA details plan to improve medical device arm; FDA panel OKs Bard's Lutonix balloon; Cohera Medical wins FDA panel date for TissuGlu surgical adhesive; FDA approves Medtronic's CoreValve for high-risk patients.
An FDA advisory panel recommends approval for C.R. Bard's Lutonix drug-eluting balloon for treating peripheral artery disease.
UPDATED June 13, 2014, with comments from panel members.
An FDA advisory panel yesterday recommended approval for the Lutonix drug-eluting balloon made by C.R. Bard (NYSE:BCR).
C.R. Bard authorizes another share repurchasing program worth $500 million.
C.R. Bard (NYSE:BCR) said it plans to buy back as much as $500 million worth of its own stock, having spent all but $30 million of a prior share repurchasing plan also worth half a billion.
Companies often buy back their stock when they believe the market is undervaluing share prices, in an effort to raise the price.